Filing Flows › Cardiff Oncology (CRDF) › Q2 2026
Cardiff Oncology (CRDF) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 11, 2026
Cardiff Oncology (CRDF) reported revenue of $104K for the second quarter 2026 (Q2 2026), -14% from a year earlier and +154% from the quarter before.
Cardiff Oncology, Q2 2026: revenue $104K (-14% year over year), net loss $9.2M, operating cash flow −$11.8M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $104K | +154% | -14% |
| Operating profit | −$9.6M | — | — |
| Net earnings | −$9.2M | — | — |
| Operating cash flow | −$11.8M | — | — |
What changed
Revenue was $104K in Q2 2026, down 14% year over year and up 154% from the previous quarter.
Operating costs exceeded revenue by $9.6M, an operating margin of -9245.2%. Total costs fell 35% while revenue fell 14%. The fastest-growing cost line was SG&A (+15%). The quarter ended with a net loss of $9.2M, narrower than the previous quarter's $12.3M loss.
Operating cash flow was −$11.8M. Non-cash charges added back $87K of depreciation and $920K of share-based compensation. Working capital and other items used $3.5M.
Questions
What was Cardiff Oncology's revenue in the second quarter 2026?
Cardiff Oncology (CRDF) reported revenue of $104K for the second quarter 2026 (Q2 2026), -14% from a year earlier and +154% from the quarter before.
Source: Cardiff Oncology 10-Q on SEC EDGAR.